These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35908023)

  • 81. Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells.
    Jeon YW; Kim OH; Shin JS; Hong HE; Kim CH; Kim SJ
    Cancer Res Treat; 2022 Jan; 54(1):157-173. PubMed ID: 33831291
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
    Lv F; Yu Y; Zhang B; Liang D; Li ZM; You W
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):870-876. PubMed ID: 24337851
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
    [No Abstract]   [Full Text] [Related]  

  • 86. Dillenia suffruticosa dichloromethane root extract induced apoptosis towards MDA-MB-231 triple-negative breast cancer cells.
    Foo JB; Saiful Yazan L; Tor YS; Wibowo A; Ismail N; Armania N; Cheah YK; Abdullah R
    J Ethnopharmacol; 2016 Jul; 187():195-204. PubMed ID: 27131434
    [TBL] [Abstract][Full Text] [Related]  

  • 87. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
    J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
    Newell M; Goruk S; Mazurak V; Postovit L; Field CJ
    Breast Cancer Res Treat; 2019 Sep; 177(2):357-367. PubMed ID: 31236812
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
    Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
    Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
    Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.
    Rontogianni S; Iskit S; van Doorn S; Peeper DS; Altelaar M
    Mol Cell Proteomics; 2020 Feb; 19(2):261-277. PubMed ID: 31772060
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy.
    Wei L; Zhang Q; Zhong C; He L; Zhang Y; Armaly AM; Aubé J; Welch DR; Xu L; Wu X
    Mol Oncol; 2023 Oct; 17(10):1962-1980. PubMed ID: 37357618
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer.
    Byun WS; Lim H; Hong J; Bae ES; Lee SB; Kim Y; Lee J; Lee SK; Hong S
    J Med Chem; 2023 Feb; 66(4):3106-3133. PubMed ID: 36786551
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.
    Kar T; Dugam P; Shivhare S; Shetty SR; Choudhury S; Sen D; Deb B; Majumdar S; Debnath S; Das A
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2049. PubMed ID: 38522013
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins.
    Ma J; Dong C; Cao YZ; Ma BL
    Breast Cancer (Dove Med Press); 2023; 15():11-24. PubMed ID: 36691572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.